Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

29.03
-0.3100-1.06%
Post-market: 29.030.00000.00%19:59 EDT
Volume:587.52K
Turnover:17.20M
Market Cap:1.87B
PE:-8.71
High:30.16
Open:29.82
Low:29.01
Close:29.34
52wk High:40.22
52wk Low:20.32
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.98
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:5.42
PE(LYR):-249.69

Loading ...

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 06

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Reuters
·
Jul 06

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 02

Stoke Therapeutics Completes Enrollment in Phase 3 Emperor Trial of Dravet Drug Zorevunersen

Reuters
·
Jun 30

Stoke Therapeutics - no Patients Have Discontinued Treatment in Phase 3 Emperor Study

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics - Phase 3 Data Readout Anticipated in Q3 2027, to Complete Nda Submission in H2 2027

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics - Plans to Initiate Rolling U.S. Nda Submission to FDA in Q1 2027

THOMSON REUTERS
·
Jun 30

Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?

Simply Wall St.
·
Jun 29

Stoke Therapeutics General Counsel Jonathan Allan sells $43,638.15 in common shares

Reuters
·
Jun 19

Stoke Therapeutics grants options for 103,020 shares to nine new employees at $30 each

Reuters
·
Jun 17

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 17

Stoke Therapeutics (STOK) Gets a Buy from Leerink Partners

TIPRANKS
·
Jun 05

Stoke Therapeutics shareholders elect three Class I directors at annual meeting

Reuters
·
Jun 05

Stoke Therapeutics CMO Barry Ticho sells 1,795 common shares for $54,886.1

Reuters
·
Jun 04

Stoke Therapeutics to present at Jefferies Global Healthcare Conference

Reuters
·
May 29

Stoke Therapeutics grants new hires options for 106,200 shares at $30.08

Reuters
·
May 19

Stoke Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Stoke Therapeutics Q1 FY26 net loss widens to $50 million; revenue drops to $6.2 million

Reuters
·
May 08

Stoke Therapeutics Q1 EPS USD -0.79

THOMSON REUTERS
·
May 08